ITCC - Innovative Therapies for Children with Cancer in Europe

Phase 1b/2 Study of Carfilzomib in combination with Dexamethasone, Mitoxantrone, PEG-asparaginase, and Vincristine (R3 Induction Backbone) in pediatric subjects with relapsed or refractory Acute Lymphoblastic Leukemia

A phase I/II study of Bosutinib in pediatric patients with Chronic Myeloid Leukemia who are resistant or intolerant to at least one prior Tyrosine Kinase Inhibitor therapy

Phase I-II Study of Vinblastine in combination with Nilotinib in children and adolescents with refractory or recurrent low-grade glioma : A SIOP and ITCC protocol

A randomised phase IIb trial of BEvACizumab added to Temozolomide ± IrinOtecan for children with refractory/relapsed Neuroblastoma

Phase I open label, dose escalation trial to determine the MTD, safety, PK and efficacy of afatinib monotherapy in children aged 2 years to <18 years with recurrent/refractory neuroectodermal tumours, rhabdomyosarcoma and/or other solid tumours with known ErbB pathway deregulation regardless of tumour histology

Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication : BIOMEDE

A Phase I/II, Multicenter, Open-Label, dose‑escalation Study of the Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients with Previously treated Solid Tumors

A phase IB study of crizotinib (Xalcori®) in pediatric malignancies with anaplastic lymphoma kinase (ALK) aberrations